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Due to the complexity of advanced radiotherapy techniques, the treatment planning process is
usually time consuming and the plan quality can vary considerably among planners and
institutions. It is also impractical to generate all possible treatment plans based on available
radiotherapy techniques and select the best option for a specific patient. Automatic dose prediction
will be very helpful in these situations, while there were a few studies of three-dimensional (3D)
dose prediction for patients who received radiotherapy. The purpose of this work was to develop a
novel atlas-based method to predict 3D dose prediction and to evaluate its performance. Previously
treated nineteen left-sided post-mastectomy breast cancer patients and sixteen prostate cancer
patients were included in this study. One patient was arbitrarily chosen as the reference for each
type of cancer and all the remaining patients’ computed tomography (CT) images and contours
were aligned to it using deformable image registration (DIR). Deformable vector field (DVF) for
each patient i (DVFi-ref) was used to deform the original 3D dose matrix of that patient. CT scan of
the test patient was also registered with the same reference patient using DIR and both direct DVF
(DVFtest-ref) and inverse DVF (DVF−1test-ref) were derived. Similarity of atlas patients to the test
patient was determined based on the similarity of DVFtest-ref to atlas DVFs (DVFi-ref) and
appropriate weighting factors were calculated. Patients’ doses in the atlas were deformed again
using DVF−1test-ref to transform them from the reference patient’s coordinates to the test patient’s
coordinates and the final 3D dose distribution for the test patient was predicted by summing the
weighted individual 3D dose distributions. Performance of our method was evaluated and the
results revealed that the proposed method was able to predict the 3D dose distributions accurately.
The mean dose difference between clinical and predicted 3D dose distributions were 0.9 ± 1.1 Gy
and 1.9 ± 1.2 Gy for breast and prostate plans. The proposed dose prediction method can be used
to improve planning quality and facilitate plan comparisons.
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The role of radiotherapy in cancer care is evolving rapidly with the adoption of new
technologies. The more advanced ones like intensity-modulated radiotherapy (IMRT) and
volumetric modulated arc therapy (VMAT) have the potential to improve treatment quality
by constraining therapeutic doses to radiosensitive organs. However, the high dose
modulation increases the complexity of treatment plans, and inverse planning is usually
iterative and time consuming. The quality of treatment plans would also vary considerably
among different planners and institutions (Das et al., 2008; Nelms et al., 2012; Batumalai et
al., 2013), which means sub-optimal treatment plans may be produced (Wu et al., 2009;
Moore et al., 2011) and may compromise patient care (Moore et al., 2015). An optimal
treatment plan for a specific patient depends on many factors and it is very challenging to
recommend a certain modality to the patient. Physicians usually make decisions based on
experience, while theoretically the planner should generate plans based on all available
radiotherapy techniques to find the best option for a patient, which is laborious and
impractical.
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Automatic dose prediction methods were proposed to reduce the planning time and improve
the plan quality. They can also be used to predict the dose distributions of different
radiotherapy techniques and facilitate plan selection. These methods could be grouped into
two main categories: one-dimensional (1D) and three-dimensional (3D) methods. The 1D
methods predict the dose volume histogram (DVH) data based on previous patient plans and
estimate target DVH objectives for new plan optimizations (Wu et al., 2011; Shiraishi et al.,
2015). These methods have limited spatial information and may constrain users’ capability
to control final dose distributions. The 3D methods predict dose on a voxel-by-voxel basis.
Shiraishi and Moore (2016) demonstrated a 3D dose prediction model using an artificial
neural network and tested applicability of their model using prostate and stereotactic
radiosurgery/radiotherapy (SRS/SRT) patients. Their model included only the voxels within
30 mm of prostate planning target volume (PTV) edge and 32 mm of SRS/SRT PTV edge.
McIntosh and Purdie (2017) reported a multiple-atlas-based dose prediction approach and
they evaluated their model for six treatment sites. Deformable image registration was used
for the comparison with their proposed dose prediction method (contextual atlas regression
forests) on atlas-dose to novel image mapping. In a separate paper, McIntosh et al. (2017)
also converted the predicted dose distributions to complete treatment plans using voxelbased dose mimicking optimization. Chen et al. (2019) used residual neural network-based
deep learning approach to generate 3D dose distribution for step-and-shoot IMRT of earlystage nasopharyngeal cancer patients. Structure images were used as the input while the
information from CT images was not considered in their study. They found including the
radiation beam geometry like distance to field boundary improved the prediction accuracy.
Fan et al. (2019) also reported a model using residual neural network-based deep learning. In
addition to 3D dose prediction for head-and-neck patient treated with step-and-shoot IMRT,
they converted the predicted doses to clinically acceptable plans by adopting a simple
objective function. Mahmood et al. (2018) reported a 3D dose prediction method based on
generative adversarial network, and they also converted predicted dose distributions to
optimized plans through inverse optimization.
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The atlas-based approach is commonly used in medical field for automatic segmentation
(Sharp et al., 2014), and the contours of a novel patient are automatically transferred from
the previously contoured atlases based on the optimal non-linear registration. Similarly, the
atlas-based approach can also be used to transfer the 3D dose distributions from the
previously planned dose files (atlases) to a novel patient (McIntosh and Purdie, 2017), but
such methods have not been extensively investigated. The purpose of this work was to
develop a simple and novel atlas-based 3D dose prediction method for radiotherapy and
evaluate its performance for breast and prostate cancer patients.

2.
2.1.

Methods and materials
Patient selection

Author Manuscript

Previously treated nineteen left-sided post-mastectomy breast cancer and sixteen prostate
cancer patients were included in this study. CT scans were acquired using a wide bore 16
slice CT scanner with 2.5mm slice thickness. All the breast patients were planned for a total
dose of 50Gy in 25 fractions using two coplanar 6 MV volumetric modulated arc therapy
(VMAT) arcs. The prostate patients were planned using two coplanar 6 MV VMAT arcs and
prescription doses were in the range of 45 –76Gy delivered in 25–38 fractions. To unify the
data, all the prostate plans were normalized to deliver 70Gy (35 fractions) to 100% PTV
volume. All the plans were created in a commercial treatment planning system (TPS)
(Pinnacle3, version 9.8, Philips Medical Systems, Fitchburg, WI). The DICOM files of each
patient including CT images, organ contours and 3D dose matrix were exported from the
TPS and anonymized (Newhauser et al., 2014) for this study.
2.2

Atlas construction
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The workflow of atlas construction is shown in figure 1 (within dashed lines). One patient
was arbitrarily chosen as the reference, and all the remaining patients’ CT and contours were
registered with the reference patient using deformable image registration (DIR). The opensource software named deformable image registration and adaptive radiotherapy (DIRART)
toolkit was used (Yang et al., 2011). During the registration process (Horn-Schunck optical
flow algorithm with default four resolution phase parameters), it is necessary to ensure
proper matching of contours between any atlas patient and the reference patient. Deformable
vector field (DVF) for each patient i derived from the above registration (DVFi-ref) will be
used to deform the original 3D dose matrix of that patient. This process was repeated for all
the patients and finally an atlas of DVFs and deformed doses (Dosei-ref) (aligned to the
reference patient) was generated (breast cancer atlas contained eighteen patients and prostate
cancer atlas contained fifteen patients because one patient in each group was chosen as the
reference and was not included in the atlas).
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2.3

Dose prediction
Figure 1 also shows the workflow of dose prediction for a test patient for which the dose is
to be predicted. CT scan of the test patient was registered with the reference patient and both
direct DVF (DVFtest-Ref) and inverse DVF (DVF−1test-Ref) were derived. Similarity of atlas
patients to the test patient was determined using DVFs based on the assumption that two
patients have similar anatomy if they have similar DVFs when they are aligned to the same
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reference patient, and similarity of DVFtest-Ref to atlas DVFs (DVFi-Ref) was measured using
structural similarity index (SSIM) (Wang et al., 2004). The SSIM measures the similarity of
two images and is calculated using the following formula:
SSIM =

μ2i

2μi μtest + c1 2σ i, test + c2

+ μ2test + c1 σ 2i + σ 2test + c2

,

(1)
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Where μi and μtest are the local means calculated over a 2D slice of DVFi-Ref and
DVFtest-Ref, σi and σtest are the local standard deviation calculated over a 2D slice of
DVFi-Ref and DVFtest-Ref, σi,test is the cross co-variance of two images, C1 and C2 are
regularization constants and are used to ensure stability when the denominator approaches
zero, i.e μ or σ is close to zero. The SSIM value was calculated for each CT slice, and the
mean SSIM index (MSSIM) of all slices was calculated as follows
∑m
i = 1SSIM i
MSSIM =
,
m

(2)
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where m is the number of CT slices for a patient. A weighting factor (Wi) was determined
for patient i in the atlas based on the MSSIM index, i.e. a higher value of Wi is assigned to a
patient with higher MSSIM index and vice-versa. Patients’ doses in the atlas will be
deformed again using DVF−1test-ref to transform them from the reference patient’s
coordinates to the test patient’s coordinates and are multiplied by the respective Wi. The
final 3D dose distribution for the test patient will be predicted by summing the weighted
individual 3D dose distributions:
D test =

∑ni = 1 Wi × Di,

(3)

where n is the total number of patients in the atlas.
2.4

Model validation
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Performance of the dose prediction model was evaluated using “leave-one-out cross
validation” approach. In this method, n-1 patients (training) were used to train the model and
the dose distribution was predicted for the one remaining patient (validation), and this
procedure is repeated for all possible combinations of training and validation data. The
predicted doses were compared with the original clinical doses: PTV coverage was evaluated
using D95% (dose to 95% of PTV volume); for breast patients, the organs at risk (OAR)
considered were heart (V22.5), total lungs (left and right combined) (V20), contralateral
breast (V5) and spinal cord (Dmax); for prostate patients, the OARs considered were rectum
(V50), bladder (V65) and right-left femoral head (V50). The parameters in the parenthesis
represent the volume of OAR receiving a particular dose value or more.
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Impact of atlas size
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In order to test the impact of total number of patients in the atlas on the accuracy of dose
prediction, the model was trained with different number of breast cancer patients (2, 5, 10
and 17), and the impact of atlas size was evaluated for five other breast cancer patients.

3.

Results
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Figure 2 shows dose volume histogram (DVH) comparisons for typical breast patients (7 and
14) and prostate patients (4 and 5): solid lines represent clinical DVH and dashed lines
represent predicted DVH. Figure 3 shows dose distribution comparison for breast cancer
patients 7 and 14 and prostate cancer patients 4 and 5. The main reasons for larger dose
deviations in breast patient 14 and prostate patient 5 are the inefficiency of registration
algorithms at high dose gradient regions (near skin surfaces) and the slightly atypical
anatomy of those patients.
Prediction accuracy of the model was analyzed. Average DVH parameters for all breast and
prostate patients are shown in figure 4. The PTV coverage was very close between predicted
and clinical plans, while OARs doses were overall lower in predicted plans. Figure 5 shows
the mean absolute dose difference (over entire CT volume) for all patients (ΔD = |Dclin −
Dpred|) and the average dose difference was observed to be 0.9 ± 1.1 Gy for breast plans and
1.9 ± 1.2 Gy for prostate plans.
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The impact of atlas size on the performance of dose prediction was also evaluated. Figure 6
shows the DVH of predicted plans for a typical breast cancer patient using various atlas
sizes. PTV coverage was very similar for all atlas sizes, but OAR doses were improved with
increased sample size. These were also demonstrated in Table 1 which shows the
comparison of mean DVH parameters (average values of 5 patients) based on various atlas
sizes.
The atlas model generation takes approximately 90 minutes for breast (18 patients) and 75
minutes for prostate (15 patients) on a 2.5 GHz Intel i5 processor with 8 GB random-access
memory (Intel Corp., Santa Clara, CA), and the model generation is required only once.
Dose prediction for a new patient takes approximately 10 minutes (5 minutes for DIR and 5
minutes for dose prediction).

4.

Discussion
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In this study, a simple and novel method was developed to predict 3D radiotherapy dose
distributions for cancer patients using weighted summation of deformed atlas doses. The
mean absolute dose difference between clinical and predicted 3D dose distributions were 0.9
± 1.1 Gy and 1.9 ± 1.2 Gy for breast and prostate plans. Our method can be used to help the
planners generate treatment plans with consistent quality and guide automated planning. It
can also facilitate faster dose evaluation and ranking of possible RT techniques, narrow
down the possible choices, and help clinical decision-making.
Compared with traditional atlas-based methods, our method only requires DIRs between the
reference patient and remaining atlas patients once and for all, and DIR between the new
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patient and the reference patient, while does not need DIR between the new patient and
remaining atlas patients. Our dose prediction takes around 10 minutes for a new patient,
which is comparable with 15 minutes run-time previously reported by McIntosh and Purdie
(2017). DIRART toolkit was also used by McIntosh and Purdie (2016, 2017) for the
comparison with their proposed dose prediction method (contextual atlas regression forests)
on atlas-dose to novel image mapping, while DIRART was the essential tool for image
deformation, generation of weighting factors and dose mapping in our study.
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The general findings of our work are consistent with literature. Shiraishi and Moore (2016)
showed that the average prediction error was less than 10% for prostate VMAT, and our
result shows 2.8 ± 2.9% for prostate VMAT. McIntosh and Purdie (2017) used the mean
absolute difference (MAD), which is the mean difference between clinical and predicted
DVHs averaged over all region of interest, to compare the clinical and predicted DVHs.
Their reported MAD values were 0.64 ± 0.43 % and 2.13 ± 0.75% for breast and prostate
patients. We also calculated the MAD values and they are 0.2 ± 3.2 % and 0.7 ± 1.9 % for
breast and prostate patients.
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It is found that PTV coverage in predicted plans does not change significantly with number
of patients used in the atlas, but OAR sparing in predicted plans improves with atlas size.
The current study included limited number of patients and only evaluated two disease sites,
while the next phase of our study will involve various sites with larger datasets. As pointed
out in the literature, atlas selection plays an important role in atlas-based techniques. Aljabar
et al. (2009) reported that selecting atlases based on image similarity and demographic
information (age) could improve the accuracy of atlas-based brain segmentation. Sanroma et
al. (2014) used a learning-based approach to select the best atlases for multiple-atlas
segmentation. McIntosh and Purdie (2016, 2017) used atlas regression forests to select the
most effective atlases for dose prediction. Unlike these work, our study uses weighted
average of atlases and includes only a relatively small sample size, which is one of the
limitations of our study. As our library size is relatively small, we chose to use all the atlases
with appropriate weighting factors which were determined based on SSIM between the atlas
patient and the novel patient. The impact of atlas selection on our method would be
interesting to investigate when a large sample sizes is used.
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The current study shows that the OAR doses of some patients are better spared in predicted
plans, so the future study should investigate the quantity of benefit from dose prediction.
McIntosh and Purdie (2017) pointed out predicted OAR sparing or better target coverage
may not actually be achievable for the real treatment, whereas Shiraishi and Moore (2016)
suggested predicted dose distributions are deliverable because they are generated based on
deliverable plans. Other studies (McIntosh et al., 2017; Mahmood et al., 2018; Fan et al.,
2019) showed that predicted 3D dose distributions can be converted to clinically acceptable
plans by adopting certain objective functions. As artificial intelligence techniques continue
to improve, it is anticipated the predicted plans will be closer and closer to deliverable plans,
but inverse planning will still be required in the dose conversion process and more
exploration in this direction is needed.
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Our DIR based method performs well on fixed anatomy like chest wall, whole breast and
prostate, whereas it may not be well suited for the freely moving anatomy like lung, breast
cavity etc., as previously discussed by McIntosh and Purdie (2017). A separate study is
needed to quantify the performance of our atlas method on these sites. The other possible
problem is that predicted patient dose may be different from clinical dose distribution for a
new patient with atypical anatomy. As shown in this study, the mean whole body dose
difference between predicted and clinical doses was low for the nineteen breast cancer and
sixteen prostate cancer patients we evaluated, so it is reasonable to expect small dose
discrepancy for most patients. We will continue to include more patients into our atlases,
predict doses, and look out for errors. To use our method for a new patient (no existing plan)
with very atypical anatomy like really obese or thin, we suggest creating one or two plans
for him or her according to clinical protocols, and comparing these plans with predicted
plans. If dose discrepancy is large, it will be prudent to create all possible plans for the
patient and include him or her in a special patient atlas.
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5.

Conclusion
This study describes a simple and novel method to predict 3D dose distributions using
weighted summation of deformed atlas doses. Performance of the dose prediction model was
evaluated for breast and prostate cancer patients. Most of the predicted plans were
comparable to clinical plans. Our method can be used to improve planning quality and
facilitate plan comparisons.
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Figure 1.

Workflow of atlas construction and dose prediction in this study. Dashed part indicates the
process of atlas construction. Wi: weighting factor for patient i; DIR: Deformable image
registration; DVF: Deformable vector field; ∑i : summation of atlas patients.
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Figure 2.
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Comparison of cumulative DVHs between clinical and predicted plans for breast cancer
patients (prescribed dose 50Gy) (a) number 7 and (b) number 14, prostate cancer patients
(prescribed dose 70Gy) (c) number 4 and (d) number 5.
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Figure 3.

Dose distribution comparison for breast patients number 7 (first row) and number 14 (second
row) and prostate patients number 4 (third row) and number 5 (fourth row). Color bars are
shown in Gy.
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Figure 4.
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Comparison of DVH parameters (mean ± sd) between clinical and predicted plans for (a)
breast cancer (n=18) and (b) prostate cancer (n=15) patients. CL-Breast: contralateral breast;
Lt FH: left femoral head; Rt FH: right femoral head.
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Figure 5.

Absolute dose difference (mean ± sd) between clinical and predicted plans for (a) all breast
patients and (b) all prostate patients. The x-axis represents patient number.
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Figure 6:

Cumulative DVH of predicted plans for a typical breast cancer patient using various atlas
sizes (2, 5, 10 and 17 samples). (a) PTV, (b) heart, (c) lungs, (d) contralateral breast and (e)
spinal cord.
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Impact of atlas size on dose prediction for 5 breast cancer patients (mean ± sd).
Parameters

2 samples

5 samples

10 samples

17 samples

PTV D95% (Gy)

47.1 ± 0.3

47.4 ± 0.2

47.2 ± 0.5

46.6 ± 0.5

Heart V22.5 (%)

10.3 ± 2.9

6.3 ± 2.0

5.2 ± 1.7

5.3 ± 2.1

Lungs V20 (%)

12.3 ± 1.4

11.1 ± 1.5

11.4 ± 1.6

11.2 ± 1.6

Contralateral Breast V5 (%)

38.1 ± 5.2

34.6 ± 9.6

33.5 ± 9.1

28.4 ± 10.3

Spinal cord Dmax (Gy)

8.7 ± 0.9

8.1 ± 0.7

9.5 ± 0.8

5.2 ± 0.5
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